RE: Collaboration with Thermo FisherToday 07:34
"What is Thermo Fisher bringing to this collaboration?"
Answer From AI
The collaboration between Genedrive plc and Thermo Fisher Scientific Inc. establishes a high-throughput commercial pathway for pharmacogenetic testing, specifically allowing Genedrive to develop and deploy its Genedrive® CYP2C19 HT Kit on Thermo Fisher’s widely used QuantStudio™ 5 Dx Real-Time PCR laboratory platform. The partnership impacts several strategic and clinical areas:
1. Market Expansion into High-Throughput Laboratories Historically, Genedrive has focused on decentralized, point-of-care testing platforms for emergency medicine. Partnering with Thermo Fisher allows Genedrive to access centralized, high-throughput laboratory networks. This broadens their commercial market, making their genetic tests accessible to large hospital labs and centralized clinical diagnostic centers that process thousands of patient samples daily.
2. Validation of Genedrive's Assay PortfolioDeveloping an in vitro diagnostic (IVD) test specifically optimized for Thermo Fisher’s QuantStudio™ 5 Dx system serves as a powerful validation of Genedrive’s chemical and technological design. Leveraging the global scale of a major clinical instrument vendor like Thermo Fisher Scientific elevates Genedrive's reputation and commercial reach.
3. Accelerated Personalized Stroke Care The CYP2C19 genetic variant dictates how effectively an individual can metabolise the common antiplatelet medication, clopidogrel. By putting Genedrive’s CYP2C19 test onto high-throughput laboratory platforms, medical teams can rapidly screen larger cohorts of stroke patients. This ensures patients who are "poor metabolisers" are quickly identified and steered toward alternative, life-saving therapies before standard prescriptions fail.